Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
- Forestier, Nicole
- Larrey, Dominique
- Marcellin, Patrick
- Guyader, Dominique
- Patat, Alain
- Rouzier, Regine
- Smith, Patrick F
- Qin, Xiaoli
- Lim, Sharlene
- Bradford, Williamson
- Porter, Steven
- Seiwert, Scott D
- Zeuzem, Stefan
DOIAbstract
International audienceBACKGROUND: Current therapy options for patients with chronic hepatitis C virus (HCV) infection genotype 1 are effective in <50%. Danoprevir (ITMN-191/RG7227) is a potent, selective, and orally active inhibitor of the HCV NS3/4A serine protease. METHODS: The safety and antiviral efficacy of danoprevir was examined over 14 days in combination with pegylated interferon α-2a (180 μg once weekly) and ribavirin (1000-1200 mg/day) in a double-blind, placebo-controlled, phase 1b, multiple ascending dose study consisting of 6 dose cohorts (400 mg, 600 mg, and 900 mg twice daily and 100 mg, 200 mg, and 300 mg 3 times daily). RESULTS: Danoprevir in combination with pegylated interferon α-2a and ribavirin was safe and generally w...
Add to ORKG